The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed scientific journals, clinical publications, patent repositories, and authoritative life sciences organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI/PubMed), World Health Organization (WHO) International Clinical Trials Registry Platform, International Society for Pharmaceutical Engineering (ISPE), Society for Laboratory Automation and Screening (SLAS), American Association for Cancer Research (AACR), European Molecular Biology Laboratory (EMBL), National Science Foundation (NSF) Science & Engineering Statistics, Organisation for Economic Co-operation and Development (OECD) Biotechnology Statistics, EU Eurostat Research & Development Database, National Bureau of Statistics of China (NBS), Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), International Federation of Pharmaceutical Manufacturers Associations (IFPMA), NIH RePORTER Database, ClinicalTrials.gov, European Patent Office (EPO), United States Patent and Trademark Office (USPTO), and national biotechnology association reports from key markets including Japan Bioindustry Association (JBA) and Korea Biotechnology Industry Organization (KoreaBIO).
Drug discovery pipeline data, clinical trial statistics, R&D expenditure trends, regulatory approval timelines for HCS-enabled therapeutics, patent filing analysis, and market landscape analysis for cell-based assays, bead-based assays, microfluidics-based assays, and automated screening platforms were all gathered from these sources.
In order to gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of Product Development, Chief Technology Officers, heads of regulatory affairs, and commercial directors from reagent suppliers, software developers, and makers of high-content screening instruments were examples of supply-side sources. Chief Scientific Officers, heads of screening operations, principal investigators, laboratory managers, and procurement leads from government research labs, academic research institutions, pharmaceutical and biotechnology companies, and contract research organizations (CROs) were examples of demand-side sources. Primary research verified product pipeline timelines for next-generation imaging platforms, validated market segmentation across applications (drug discovery and development, biomarker discovery, cell biology research), and acquired information on technology adoption trends, pricing strategies for automated versus semi-automated platforms, and funding dynamics for academic HCS facility investments.
Primary Respondent Breakdown:
By Designation: C-level Primaries (28%), Director Level (32%), Others (40%)
By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)
Global market valuation was derived through revenue mapping and instrument installation base analysis. The methodology included:
Identification of 35+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America specializing in imaging systems, liquid handling robotics, and HCS software solutions
Product mapping across cell-based assays, bead-based assays, microfluidics-based assays, and emerging organoid-based screening technologies
Analysis of reported and modeled annual revenues specific to high-content screening portfolios, including hardware, consumables, and software/services revenue streams
Coverage of manufacturers representing 75-80% of global market share in 2024
Extrapolation using bottom-up (installed base × service contract value + new instrument sales by country) and top-down (manufacturer revenue validation against public filings and industry estimates) approaches to derive segment-specific valuations for automated platforms, semi-automated platforms, and manual screening systems
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
Noah Malgeri
Co-Founder
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
Joseph Aguayo
Sales Operations & Pricing Manager
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
Peter Groot koerkamp
Account and Business Manager
“Thank you, this will be very helpful for OQS.”
La Terria Dodd
Program Support Specialist
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
Younghwan Choi
Senior Retail Manager
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile").
In general the report is well structured. Thanks very much for your efforts.”
Mark Irwin
Management Consultant
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
Rob Kooiker
Group Product Manager HVAC & Fire Protection GMA
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
Akif Moroglu
Strategy & Business Development Director
.png?v=1778851878)
